Argenx has witnessed unfolding stories over the past year. The company announced their Annual General Meeting set for May 2026 while also revealing changes in board membership with Jim Daly's announced exit. A renewed focus on Vyvgart, Argenx's potential drug candidate for ocular myasthenia gravis, has seen promising data emerge regarding early disease control, causing analysts to highlight Vyvgart expansion as a key growth driver for Argenx. Argenx has demonstrated financial strength, posting their first annual profit of over 1 billion dollars and increasing 2025 sales to $4.2B. The company experienced leadership transition with the CEO set to step down in May, to be succeeded by their COO. Despite the discontinuation of phase 3 UplighTED trials of efgartigimod SC in thyroid eye disease following a clinical setback, optimism remains high for Vyvgart. The top-line results from phase 3 have been found to be positive, and Argenx has been said to outperform its competitors. There has also been a collaboration effort with Tennis Legend Monica Seles to raise awareness of Myasthenia Gravis.
argenx News Analytics from Tue, 01 Jul 2025 07:00:00 GMT to Fri, 20 Mar 2026 21:22:32 GMT -
Rating 8
- Innovation 7
- Information 9
- Rumor 5
